Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (543)	3/4/2004 11:54:06 PM
From: Jibacoa	Respond to of 3722

INGN Also closed at its intraday H albeit it was down $0.02 after hours.<g> Last week it reported good progress for the 4thQ and fiscal Yr on its research and clinical trial programs. The net loss for the Q of $5.4M was less than the $5.6M in 2002, albeit higher than the $4.4M on the previous Q which included some earnings from a litigation settlement on its favor.<g> For the Yr. it reported a loss of $19.3M or $0.84/share.(That was less than the $26.1M or $1.22/share in 2002) During the 4th Q its cash and cash position increased $13.8M as a result of net proceeds of $18.6M from the sale of stock, offset by $4.8M that were for operations.(As of Dec.31, it had $36.4M in cash.) In February it also presented at the Society of University Surgeons 65th Annual Meeting, preclinical data supporting the use of INGN 241 for the treatment of lung and breast Ca. The combination of INGN 241 and DNA's Herceptin showed promising results in breast Ca. INGN has completed a PI/II with INGN 241 and the data showed that the drug has activity as a monotherapy in several cancer indications. Due to the multi-functional activity of mda-7/IL-24, which acts as a tumor suppressor, a potent inhibitor of angiogenesis and an immunostimulating cytokine, INGN 241 may have broad utility as a monotherapy or as a component of combination regimens in a variety of cancer indications. The stock needs to close above its January 26 H of 10.20 before it can test its January 13 H at 10.37 <g> (After doing that the September H at 11.24 should not be of any major problem, especially with the ASCO meeting coming soon.<g> bigcharts.marketwatch.com I am still looking for the stock to test its October 2000 H at 15.50 level this year.<g> bigcharts.marketwatch.com Caveat: I am long on INGN and probably biassed.<g> Bernard